

CANADIAN CANCER TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

Saturday 30 April 2016, 1:30-4:15 PM

Chelsea Hotel, Toronto

Room: Churchill A

Chairs: G. Goss / Y. Ung

Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

1:30 – 1:35 pm	Welcome and Introduction	G. Goss/Y. Ung
1:35 – 2:05 pm	Plenary Session: <i>Progress in medical treatment of lung cancer, at which cost?</i>	F. Perrone
2:05 – 2:55 pm	<u>Report from Study Chairs: Update on Current Trials</u>	
2:05 – 2:15	<u>BRC.5:</u> A Phase III Randomized Trial Of Lobectomy Versus Sublobar Resection For Small (< 2cm) Peripheral Non-Small Cell Lung Cancer	G. Darling
2:15 – 2:25	<u>BR31:</u> A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non Small Cell Lung Cancer	G. Goss
2:25 – 2:35	<u>BRC.6 (LungMAP – S1400):</u> A Phase II/III Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer	N. Leighl
2:35 – 2:45	<u>BR.34:</u> A Phase III Randomized Trials of the Anti-PD-L1 Monoclonal Antibody, Durvalumab ± Tremelimumab and Chemotherapy as First-Line Therapy In Advanced (Stage IIIB/IV) Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	N. Leighl
2:45 – 2:55	<u>BR.35:</u> A randomized Phase II Study of Precision Radiotherapy for Oligometastatic Non-Small cell lung cancer (PROMISE-NSCLC)	P. Cheung

2:55 – 3:05 pm **Coffee Break**

IND Studies

- 3:05 – 3:15 **IND.211: Final Report** **D. Morris**
 A Randomized Phase II Study Of Reolysin in Patients with Previously Treated Advanced Or Metastatic Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
- 3:15 – 3:20 **IND.219:** **B. Melosky/P. Bradbury**
 A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment Of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non Small Cell Lung Cancer
- 3:20 – 3:25 **IND.226:** **R. Juergens/D. Hao**
 A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
- 3:25 – 3:30 **IND.227:** **Q. Chu**
 A Phase II Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- 3:30 – 3:35 **IND.233:** **M. Mates/V. Hirsh**
 A Phase II Randomized Study of Erlotinib With or Without Xilonex in Patients with Advanced Non-Small Cell Lung Cancer

Reports from Committees

- 3:35 - 3:45 **Report from IND Committee** **S. Laurie**
- 3:45 – 3:55 **Report from Lung CSTB** **M. Tsao**
- 3:55 – 4:15 **New Concepts and Proposals** **Y.Ung, P. Ellis, C. Lee**
- 4.15 pm **Summary and Close** **G. Goss/Y. Ung**